Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement. Issue 9 (7th September 2020)

• Record Type: Journal Article
• Authors: Mooneyham, Jesse; Gentille, Cesar; Barbieri, Andrea; Shah, Shilpan
• Is Part Of: BMJ case reports. Volume 13:Issue 9(2020)
• Publication Date: 2020-09-07
• Subjects: haematology (drugs and medicines) -- malignant disease and immunosuppression -- malignant and benign haematology -- neurooncology -- neurosurgery; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2020-235412
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : A 33-year-old woman presented to the emergency room with severe headaches. A CT scan of the head revealed two brain lesions with associated vasogenic oedema. Diagnostic resection of one of the lesions followed by pathological analysis revealed grade III lymphomatoid granulomatosis (LYG). Staging investigations elsewhere in the body were negative, isolating this case of LYG to the central nervous system, an atypical presentation. After the resection, she was treated with single-agent rituximab 375 mg/m 2 . The follow-up MRI demonstrated the resolution of brain lesions and no progression of the disease.